My research activities involve initiating clinical trials in renal cancer and prostate cancer, and technology assessment as applied to the introduction of minimally invasive surgery.
Identification of subgroups of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone plus prednisone at low vs. high risk of radiographic progression: An analysis of COU-AA-302.
Can Urol Assoc J. 2018 Nov 05;:
Nat Commun. 2018 Nov 05;9(1):4616
Eur Urol. 2018 Sep 05;:
Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline.
J Clin Oncol. 2018 Sep 05;:JCO1800606
International multi-center validation of an intermediate-risk subclassification of prostate cancer treated with radical treatment without hormone therapy.
J Urol. 2018 Aug 25;:
Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma.
Can Urol Assoc J. 2018 Aug;12(8):231-238
Preoperative Brimonidine Tartrate 0.2% does not Prevent an Intraocular Pressure Rise During Prostatectomy in Steep Trendelenburg Position.
J Glaucoma. 2018 Aug 07;:
J Urol. 2018 Jul 20;:
Renal tumor biopsy: indicators, technique, safety, accuracy results, and impact on treatment decision management.
World J Urol. 2018 Jul 18;:
The association between physician trust and prostate-specific antigen screening: Implications for shared decision-making.
Can Urol Assoc J. 2018 Jun 19;:
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Assistant Professor, Departments of Surgery and Oncology, University of Toronto
Staff Surgeon, Surgical Oncology, Division of Urology, University Health Network